CervoMed, Inc. (CRVO)
2.44
+0.01
(+0.41%)
USD |
NASDAQ |
Sep 21, 16:00
2.44
0.00 (0.00%)
After-Hours: 20:00
CervoMed EPS Diluted (Quarterly) : -0.6415 for June 30, 2026
EPS Diluted (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.6415 |
| March 31, 2026 | -0.8602 |
| December 31, 2025 | -0.874 |
| September 30, 2025 | -0.8351 |
| June 30, 2025 | -0.6992 |
| March 31, 2025 | -0.5624 |
| December 31, 2024 | -0.7987 |
| September 30, 2024 | -0.5462 |
| June 30, 2024 | -0.2662 |
| March 31, 2024 | -0.4075 |
| December 31, 2023 | -0.4163 |
| September 30, 2023 | -0.6977 |
| June 30, 2023 | -2.751 |
| March 31, 2023 | -1.031 |
| December 31, 2022 | -2.948 |
| September 30, 2022 | -2.555 |
| June 30, 2022 | -3.083 |
| March 31, 2022 | -3.332 |
| December 31, 2021 | -2.557 |
| September 30, 2021 | -8.978 |
| June 30, 2021 | -2.780 |
| March 31, 2021 | -4.175 |
| December 31, 2020 | -4.759 |
| September 30, 2020 | -5.201 |
| June 30, 2020 | -7.324 |
| Date | Value |
|---|---|
| March 31, 2020 | -5.561 |
| December 31, 2019 | -8.405 |
| September 30, 2019 | -44.81 |
| June 30, 2019 | -47.49 |
| March 31, 2019 | -61.04 |
| December 31, 2018 | -123.75 |
| September 30, 2018 | -149.48 |
| June 30, 2018 | -56.25 |
| March 31, 2018 | -303.75 |
| December 31, 2017 | -123.75 |
| September 30, 2017 | 225.00 |
| June 30, 2017 | -1125.00 |
| March 31, 2017 | -3127.50 |
| December 31, 2016 | -279.54 |
| September 30, 2016 | -596.25 |
| June 30, 2016 | -450.00 |
| March 31, 2016 | -675.00 |
| December 31, 2015 | -1879.76 |
| September 30, 2015 | -7200.00 |
| June 30, 2015 | -2362.50 |
| March 31, 2015 | 0.00 |
| December 31, 2014 | -3062.81 |
| September 30, 2014 | -2025.00 |
| June 30, 2014 | -3937.50 |
| March 31, 2014 | -2587.50 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
| Anika Therapeutics, Inc. | 0.2412 |
| Savara, Inc. | -0.1587 |
| Vericel Corp. | 0.0422 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -6.572M |
| Total Expenses (Quarterly) | 6.572M |
| Enterprise Value | 7.930M |
| Earnings Yield | -131.6% |
| Normalized Earnings Yield | -131.59 |